, Volume 64, Issue 20, pp 2273–2289 | Cite as

Slowing the Progression of Adult Chronic Kidney Disease

Therapeutic Advances
Therapy In Practice


When kidney disease of any aetiology results in substantial loss of nephrons, a common clinical syndrome, characterised by hypertension, proteinuria and a progressive decline in renal function, ensues. This observation suggests that common mechanisms may contribute to progressive renal injury and that therapeutic interventions that inhibit these common pathways may afford renal protection. Research to date has identified several mechanisms that may contribute to progressive renal injury including glomerular haemodynamic changes, multiple effects of angiotensin II and detrimental effects of excessive filtration of plasma proteins by injured glomeruli. Clinical trials over the past decade have identified several interventions that are effective in slowing the rate of progression of chronic kidney disease (CKD). The use of ACE inhibitors, angiotensin receptor antagonists or a combination of the two should be regarded as fundamental to any therapy for slowing the rate of CKD progression. Hypertension should be treated aggressively to achieve a blood pressure target of <130/80mm Hg. Reduction of proteinuria to <0.5 g/day should be regarded as an independent therapeutic goal. Although inconclusive, there is some evidence to support moderate dietary protein restriction to 0.6 g/kg/day in appropriate patients. Hyperlipidaemia may contribute to CKD progression and should be treated to reduce cardiovascular risk and potentially improve renal protection. Smoking cessation should be encouraged and, where necessary, assisted. Among diabetic patients tight glycaemic control should be achieved (glycosylated haemoglobin <7%). These interventions are simple and relatively inexpensive. If applied to all patients with CKD they will result in substantial slowing of renal function decline in many patients and thereby reduce the number who progress to end-stage renal disease and require renal replacement therapy.



No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 108–20PubMedCrossRefGoogle Scholar
  2. 2.
    Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85–93PubMedGoogle Scholar
  3. 3.
    Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993–2000PubMedCrossRefGoogle Scholar
  4. 4.
    Zatz R, Meyer TW, Rennke HG, et al. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 1985; 82: 5963–7PubMedCrossRefGoogle Scholar
  5. 5.
    Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925–30PubMedCrossRefGoogle Scholar
  6. 6.
    Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens 2004; 13: 31–7PubMedCrossRefGoogle Scholar
  7. 7.
    Abbate M, Zoja C, Morigi M, et al. Transforming growth factor-betal is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathology 2002; 161: 2179–93CrossRefGoogle Scholar
  8. 8.
    Lapinski R, Perico N, Remuzzi A, et al. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996; 7: 653–60PubMedGoogle Scholar
  9. 9.
    Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803–17PubMedCrossRefGoogle Scholar
  10. 10.
    Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–8PubMedCrossRefGoogle Scholar
  11. 11.
    Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County (MD). J Am Soc Nephrol 2003; 14: 2934–41PubMedCrossRefGoogle Scholar
  12. 12.
    Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; I(8335): 1175–9CrossRefGoogle Scholar
  13. 13.
    Bergstrom J, Alvestrand A, Bucht H, et al. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 1986; 25: 1–6PubMedGoogle Scholar
  14. 14.
    Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990; 37: 1113–9PubMedCrossRefGoogle Scholar
  15. 15.
    Kes P, Ratkovic-Gusic I. The role of arterial hypertension in progression of renal failure. Kidney Int Suppl 1996; 55: S72–4PubMedGoogle Scholar
  16. 16.
    Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877–84PubMedCrossRefGoogle Scholar
  17. 17.
    Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754–62PubMedGoogle Scholar
  18. 18.
    Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34: 809–17PubMedCrossRefGoogle Scholar
  19. 19.
    Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646–61Google Scholar
  20. 20.
    Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26: S80–2PubMedCrossRefGoogle Scholar
  21. 21.
    National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39: S1–S246CrossRefGoogle Scholar
  22. 22.
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2004; 43: 1–3Google Scholar
  23. 23.
    ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97CrossRefGoogle Scholar
  24. 24.
    Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793–800PubMedCrossRefGoogle Scholar
  25. 25.
    Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452–8PubMedCrossRefGoogle Scholar
  26. 26.
    Ruggenenti P, Perna A, Benini R, et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies: Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998; 9: 2096–101PubMedGoogle Scholar
  27. 27.
    Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719–28PubMedCrossRefGoogle Scholar
  28. 28.
    Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283–9PubMedCrossRefGoogle Scholar
  29. 29.
    Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–63CrossRefGoogle Scholar
  30. 30.
    Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254–61PubMedCrossRefGoogle Scholar
  31. 31.
    Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131–40PubMedCrossRefGoogle Scholar
  32. 32.
    Brenner BM. Retarding the progression of renal disease. Kidney Int 2003; 64: 370–8PubMedCrossRefGoogle Scholar
  33. 33.
    Schieppati A, Remuzzi G. The future of renoprotection: frustration and promises. Kidney Int 2003; 64: 1947–55PubMedCrossRefGoogle Scholar
  34. 34.
    Wilmer WA, Rovin BH, Hebert CJ, et al. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003; 14: 3217–32PubMedCrossRefGoogle Scholar
  35. 35.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62PubMedCrossRefGoogle Scholar
  36. 36.
    Brenner BM, Cooper ME, de Zeeuw D, etal. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9PubMedCrossRefGoogle Scholar
  37. 37.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60PubMedCrossRefGoogle Scholar
  38. 38.
    Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359–64PubMedCrossRefGoogle Scholar
  39. 39.
    Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117–24PubMedCrossRefGoogle Scholar
  40. 40.
    The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370–9Google Scholar
  41. 41.
    The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria: the EUCLID Study Group. Lancet 1997; 349: 1787–92CrossRefGoogle Scholar
  42. 42.
    UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998; 317: 713–20CrossRefGoogle Scholar
  43. 43.
    Sano T, Kawamura T, Matsumae H, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17: 420–4PubMedCrossRefGoogle Scholar
  44. 44.
    Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulindependent diabetic patients: North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995; 8: 876–83PubMedCrossRefGoogle Scholar
  45. 45.
    Agardh CD, Garcia-Puig J, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185–92PubMedGoogle Scholar
  46. 46.
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9CrossRefGoogle Scholar
  47. 47.
    Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156: 286–9PubMedCrossRefGoogle Scholar
  48. 48.
    Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576–81PubMedCrossRefGoogle Scholar
  49. 49.
    Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601–6PubMedCrossRefGoogle Scholar
  50. 50.
    Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1998; 128 (12 Pt 1): 982–8PubMedGoogle Scholar
  51. 51.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8PubMedCrossRefGoogle Scholar
  52. 52.
    Mogensen CE, Noltham S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in pateints with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–4PubMedCrossRefGoogle Scholar
  53. 53.
    Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641–50PubMedCrossRefGoogle Scholar
  54. 54.
    Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150–5PubMedCrossRefGoogle Scholar
  55. 55.
    Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182–8PubMedCrossRefGoogle Scholar
  56. 56.
    Fogari R, Zoppi A, Corradi L, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47–53PubMedCrossRefGoogle Scholar
  57. 57.
    Maschio G, Alberti D, Janin G, et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939–45PubMedCrossRefGoogle Scholar
  58. 58.
    Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73–87PubMedGoogle Scholar
  59. 59.
    Praga M, Gutierrez E, Gonzalez E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578–83PubMedCrossRefGoogle Scholar
  60. 60.
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53CrossRefGoogle Scholar
  61. 61.
    Arakawa K. Serine protease angiotensin II systems. J Hypertens Suppl 1996; 5: S3–7Google Scholar
  62. 62.
    Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–8PubMedCrossRefGoogle Scholar
  63. 63.
    Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001; 345: 910–1PubMedCrossRefGoogle Scholar
  64. 64.
    Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–5PubMedCrossRefGoogle Scholar
  65. 65.
    Weber M. Clinical safety and tolerability of losartan. Clin Ther 1997; 19: 604–16PubMedCrossRefGoogle Scholar
  66. 66.
    Lacourciere Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough: Losartan Cough Study Group. J Hypertens 1994; 12: 1387–93PubMedGoogle Scholar
  67. 67.
    Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101–7PubMedGoogle Scholar
  68. 68.
    Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria [published erratum appears in Nephrol Dial Transplant 2002 Jun;17 (6): 1153]. Nephrol Dial Transplant 2002; 17: 597–601PubMedCrossRefGoogle Scholar
  69. 69.
    Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease: European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000; 18: 89–95PubMedCrossRefGoogle Scholar
  70. 70.
    Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094–103PubMedCrossRefGoogle Scholar
  71. 71.
    Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002; 17: 1019–24PubMedCrossRefGoogle Scholar
  72. 72.
    Rossing K, Christensen PK, Jensen BR, et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabetes Care 2002; 25: 95–100PubMedCrossRefGoogle Scholar
  73. 73.
    Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601–8PubMedCrossRefGoogle Scholar
  74. 74.
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685–93PubMedCrossRefGoogle Scholar
  75. 75.
    McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71PubMedCrossRefGoogle Scholar
  76. 76.
    Levey AS, Adler S, Greene T, et al. Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1996; 7: 2616–26Google Scholar
  77. 77.
    Levey AS, Adler S, Caggiula AW, et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1996; 27: 652–63PubMedCrossRefGoogle Scholar
  78. 78.
    Pedrini MT, Levey AS, Lau J, et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 124: 627–32PubMedGoogle Scholar
  79. 79.
    Monzani G, Bergesio F, Ciuti R, et al. Lipoprotein abnormalities in chronic renal failure and dialysis patients. Blood Purif 1996; 14: 262–72PubMedCrossRefGoogle Scholar
  80. 80.
    Kasiske BL, O’Donnel MP, Garvis WJ, et al. Pharmacologic treatment of hyperlipidemia reduces injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62: 367–74PubMedCrossRefGoogle Scholar
  81. 81.
    O’Donell MP, Kasiske BL, Kim Y, et al. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 1993; 22: 83–9Google Scholar
  82. 82.
    Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13: 2898–908PubMedCrossRefGoogle Scholar
  83. 83.
    Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260–9PubMedCrossRefGoogle Scholar
  84. 84.
    Ruggenenti P, Mise N, Pisoni R, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003; 107: 586–92PubMedCrossRefGoogle Scholar
  85. 85.
    Chase HP, Garg SK, Marshall G, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991; 265: 614–7PubMedCrossRefGoogle Scholar
  86. 86.
    McKenna K, Thompson C. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus. Scott Med J 1997; 42: 99–104PubMedGoogle Scholar
  87. 87.
    Muhlhauser I, Overmann H, Bender R, et al. Predictors of mortality and end-stage diabetic complications in patients with type 1 diabetes mellitus on intensified insulin therapy. Diabet Med 2000; 17: 727–34PubMedCrossRefGoogle Scholar
  88. 88.
    Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000; 35: 687–94PubMedCrossRefGoogle Scholar
  89. 89.
    Stengel B, Couchoud C, Cenee S, et al. Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies. Kidney Int 2000; 57: 2519–26PubMedGoogle Scholar
  90. 90.
    Orth SR, Stockmann A, Conradt C, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54: 926–31PubMedCrossRefGoogle Scholar
  91. 91.
    Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082–8PubMedCrossRefGoogle Scholar
  92. 92.
    The Diabetes Control and Complications (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86CrossRefGoogle Scholar
  93. 93.
    Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17PubMedCrossRefGoogle Scholar
  94. 94.
    Feldt-Rasmussen B, Mathiesen ER, Decken T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2: 1300–4PubMedCrossRefGoogle Scholar
  95. 95.
    Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304–9PubMedCrossRefGoogle Scholar
  96. 96.
    Bangstad HJ, Osterby R, Dahl-Jorgensen K, et al. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483–90PubMedCrossRefGoogle Scholar
  97. 97.
    Microalbuminuria Collaborative Study Group, United Kingdom. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311: 973–7CrossRefGoogle Scholar
  98. 98.
    The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703–20CrossRefGoogle Scholar
  99. 99.
    Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69–75PubMedCrossRefGoogle Scholar
  100. 100.
    UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRefGoogle Scholar
  101. 101.
    National Kidney Foundation [online]. Available from URL: http://www.kidney.org [Accessed 2004 Jul 29]

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of Renal MedicineDerby City General HospitalDerbyUK
  2. 2.Centre for Integrated Systems in Biology and MedicineNottingham UniversityNottinghamUK

Personalised recommendations